Overview

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of an 800-mg single dose of TMC207 on the QT/QTc interval in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Tibotec BVBA
Treatments:
Bedaquiline
Diarylquinolines
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination